Skip to main content

Peer Review reports

From: Brigatinib versus other second-generation ALK inhibitors as initial treatment of anaplastic lymphoma kinase positive non-small cell lung cancer with deep phenotyping: study protocol of the ABP trial

Original Submission
25 Nov 2020 Submitted Original manuscript
30 Apr 2021 Reviewed Reviewer Report - Adrianus J de Langen
3 May 2021 Reviewed Reviewer Report
25 May 2021 Author responded Author comments - Petros Christopoulos
Resubmission - Version 2
25 May 2021 Submitted Manuscript version 2
8 Jun 2021 Editorially accepted
28 Jun 2021 Article published 10.1186/s12885-021-08460-w

You can find further information about peer review here.

Back to article page